Alamifovir

DB06368ExperimentalSmall molecule

Alamifovir is an antiviral agent specific for HBV.

Mechanism: Alamifovir is a purine nucleotide analogue prodrug that shows potent activity against wild type and lamivudine resistant hepatitis B virus in preclinical studies.
Curator reviewed
Primary indication: Investigated for use/treatment in hepatitis (viral, B).Curator reviewed
Formula / weight: C₁₉H₂₀F₆N₅O₅PS · 575.42 g/mol (avg)
Code names: LY-582563 · MCC-478

Resolves to

Compound

Structure

InChIKeyVDBGPMJFHCJMOL-UHFFFAOYSA-NSMILESCOC1=CC=C(SC2=C3N=CN(CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F)C3=NC(N)=N2)C=C1

What you can answer from here — as of March 06, 2025

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Alamifovir, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.